Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.39 and traded as high as $4.62. Puma Biotechnology shares last traded at $4.42, with a volume of 144,087 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Puma Biotechnology in a report on Wednesday, October 12th. They issued a "buy" rating for the company.

Puma Biotechnology Price Performance

The stock has a fifty day moving average of $4.51 and a 200-day moving average of $3.39. The company has a quick ratio of 1.95, a current ratio of 2.04 and a debt-to-equity ratio of 4.42. The stock has a market capitalization of $201.73 million, a price-to-earnings ratio of 20.09, a P/E/G ratio of 2.00 and a beta of 0.92.

Insider Activity

In other news, CEO Alan H. Auerbach sold 27,241 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total value of $113,867.38. Following the completion of the sale, the chief executive officer now directly owns 6,852,638 shares of the company's stock, valued at $28,644,026.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Alan H. Auerbach sold 27,241 shares of the company's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total transaction of $113,867.38. Following the completion of the sale, the chief executive officer now owns 6,852,638 shares in the company, valued at $28,644,026.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Maximo F. Nougues sold 10,499 shares of the company's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total value of $43,885.82. Following the sale, the chief financial officer now owns 100,427 shares of the company's stock, valued at approximately $419,784.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,034 shares of company stock valued at $176,343. 21.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Federated Hermes Inc. raised its position in Puma Biotechnology by 1.2% in the third quarter. Federated Hermes Inc. now owns 355,368 shares of the biopharmaceutical company's stock worth $842,000 after acquiring an additional 4,251 shares in the last quarter. BNP Paribas Arbitrage SNC increased its position in shares of Puma Biotechnology by 45.3% in the third quarter. BNP Paribas Arbitrage SNC now owns 19,918 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 6,212 shares in the last quarter. Panagora Asset Management Inc. increased its position in shares of Puma Biotechnology by 3.6% in the first quarter. Panagora Asset Management Inc. now owns 205,138 shares of the biopharmaceutical company's stock valued at $591,000 after buying an additional 7,066 shares in the last quarter. Prudential Financial Inc. increased its position in shares of Puma Biotechnology by 4.8% in the first quarter. Prudential Financial Inc. now owns 186,936 shares of the biopharmaceutical company's stock valued at $539,000 after buying an additional 8,500 shares in the last quarter. Finally, UBS Group AG increased its position in shares of Puma Biotechnology by 48.8% in the first quarter. UBS Group AG now owns 25,985 shares of the biopharmaceutical company's stock valued at $75,000 after buying an additional 8,523 shares in the last quarter. Hedge funds and other institutional investors own 60.58% of the company's stock.

About Puma Biotechnology

(Get Rating)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

Featured Articles

• Get a free copy of the StockNews.com research report on Puma Biotechnology (PBYI)
• Chevron Delights Shareholders with $75 Billion in Share Buybacks
• The Future Of E-Commerce: Analysis And New Data
• Levi Strauss Is A Good Fit For Income Investors
• 3 Small Caps That Have Big Upside
• Mullen Automotive: The Good News, The Bad And The Ugly Outlook

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.